Examining apixaban vs aspirin in patients with cancer and cryptogenic stroke

Ochsner Health physicians Dr. Richard Zweifler and Dr. Joseph Tarsia are co-authors on a post hoc analysis carried out in the ARCADIA randomized clinical trial, comparing the effectiveness of apixaban versus aspirin in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke. The research found no significant difference in the risk of major ischemic and hemorrhagic events between those taking apixaban and aspirin. The study was published in the JAMA Neurology journal.

Facebook Comments